Butyrophenone antipsychotic

This page covers all Butyrophenone antipsychotic drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Dopamine D2 receptor.

Targets

Dopamine D2 receptor

Phase 3 pipeline (1)

• Droperidol Injectable Product · Mercy Health Ohio · Psychiatry / Acute Care
  Droperidol is a butyrophenone antipsychotic that blocks dopamine receptors in the central nervous system, reducing agitation and providing antiemetic effects.

Patent intelligence

• butyrophenone antipsychotic patent landscape — aggregated cliff calendar, attackable patents, originator estates